Trials / Completed
CompletedNCT02359201
Assessment of V0018 1.5 mg Effect on Craving
Double-blind, Randomized, Placebo-controlled, Cross-over Study of the Effect of a 1.5 mg Nicotine Lozenge on Smoking Craving
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Pierre Fabre Medicament · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the reduction of craving after administration of V0018 1.5 mg compared to placebo in healthy moderately dependent smokers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | V0018 | Oromucosal - Single dose |
| DRUG | Placebo | Oromucosal - Single dose |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2015-02-09
- Last updated
- 2015-04-21
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02359201. Inclusion in this directory is not an endorsement.